Video taking off 16x its usual first day

Martin Shkreli brings his quantum skepticism to All-In

The interview moves from pharmaceutical pricing to lessons from prison, while viewers keep asking for a longer conversation.

Channel:

All-In Podcast Story of October 13, 2026Trari Newsroom

Why this story? The video opened at a pace of 176,184 views a day, 16 times a normal first day on this channel (10,869).

Martin Shkreli: Big Pharma's Blind Spot, Betting Against Quantum & What Prison Taught Him

Martin Shkreli opens his All-In appearance with a bet against quantum computing, not a pitch for its future. The interview then moves into pharmaceutical pricing, AI drug discovery and what he learned in prison, a broader conversation than its opening might suggest.

It reached about 116,000 views in 11 hours, already far beyond the channel's usual full-day audience for regular videos. The comment section was also more than twice as busy as a typical first day. A recurring request runs through the responses: give Shkreli more time, preferably in a longer podcast interview.

The description frames his quantum argument as skepticism about what he calls a one-trick business. On pharmaceuticals, he discusses his move from hedge fund trading into the industry and argues that some drugs are sold too cheaply. The AI section asks who actually benefits from advances in drug discovery, before the conversation turns to rule-breaking, the gifted-kid trap and his experience of prison. The episode includes sponsor acknowledgments.

Technology's effect on business value also appears in another fast-starting All-In upload, "Chamath: Software IP Just Became Worthless." That Short is drawing an unusually large early audience too, but the Shkreli interview gives viewers several distinct arguments to chew over, and their requests for a longer return visit are unusually consistent.

Published on Trari